Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment

Introduction: This open label, multicentre study was conducted to assess the times to offset of the pharmacodynamic effects and the safety of remifentanil in patients with varying degrees of renal impairment requiring in
Introduction: This open label, multicentre study was conducted to assess the times to offset of the pharmacodynamic effects and the safety of remifentanil in patients with varying degrees of renal impairment requiring intensive care.
Methods: A total of 40 patients, who were aged 18 years or older and had normal/mildly impaired renal function (estimated creatinine clearance ≥ 50 ml/min; n = 10) or moderate/severe renal impairment (estimated creatinine clearance <50 ml/min; n = 30), were entered into the study. Remifentanil was infused for up to 72 hours (initial rate 6–9 μg/kg per hour), with propofol administered if required, to achieve a target Sedation–Agitation Scale score of 2–4, with no or mild pain.
Results: There was no evidence of increased offset time with increased duration of exposure to remifentanil in either group. The time to offset of the effects of remifentanil (at 8, 24, 48 and 72 hours during scheduled down-titrations of the infusion) were more variable and were statistically significantly longer in the moderate/severe group than in the normal/mild group at 24 hours and 72 hours. These observed differences were not clinically significant (the difference in mean offset at 72 hours was only 16.5 min). Propofol consumption was lower with the remifentanil based technique than with hypnotic based sedative techniques. There were no statistically significant differences between the renal function groups in the incidence of adverse events, and no deaths were attributable to remifentanil use.
Conclusion: Remifentanil was well tolerated, and the offset of pharmacodynamic effects was not prolonged either as a result of renal dysfunction or prolonged infusion up to 72 hours.
show moreshow less

Download full text files

Export metadata

  • Export Bibtex
  • Export RIS
Metadaten
Author:Des Breen, Alexander Wilmer, Andrew Bodenham, Vagn Bach, Jan Bonde, Paul Kessler, Sven Albrecht, Soraya Shaikh
URN:urn:nbn:de:hebis:30-11487
DOI:http://dx.doi.org/10.1186/cc2399
ISSN:1466-609X
ISSN:1364-8535
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=14975051
Parent Title (English):Critical care
Publisher:BioMed Central ; Springer
Place of publication:London ; Berlin ; Heidelberg
Document Type:Article
Language:English
Year of Completion:2003
Date of first Publication:2003/11/21
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2005/06/22
Tag:analgesia based sedation; critical care; offset times; pharmacodynamics; remifentanil; renal function; safety
Volume:8
Issue:1
Pagenumber:10
First Page:R21
Last Page:R30
Note:
Copyright: © Breen et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. 2004
Source:Critical Care 2004, 8:R1-R11 (20 November 2003) , http://ccforum.com/content/8/1/R21
HeBIS PPN:197115446
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License Logo Veröffentlichungsvertrag für Publikationen

$Rev: 11761 $